Migoprotafib

Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity[1][2].

Product Specifications

CAS Number

[2377352-49-1]

Product Name Alternative

GDC-1971

UNSPSC

12352005

Target

ERK; p38 MAPK; Phosphatase; SHP2

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/r-gdc-1971.html

Purity

98.81

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N[C@H]1C2(CCN(C3=CN=C(C(N4C5=CC=CN=C5CCC4)=NN6)C6=N3)CC2)OC7=CC=CC=C71

Molecular Formula

C25H26N8O

Molecular Weight

454.53

References & Citations

[1]Alexander M, et al. Shp2 phosphatase inhibitors and methods of use thereof. Patent WO2019183367A1.|[2]Maddalo D, et al. RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy[J]. 2024.